Lung involvement in connective tissue diseases


Authors: M. Vašáková
Authors‘ workplace: Pneumologická klinika 1. LF UK, Fakultní Thomayerova nemocnice s poliklinikou
Published in: Čes. Revmatol., 18, 2010, No. 4, p. 192-200.
Category: Overview Reports

Overview

Lung involvement in connective tissue diseases (CTDs) is relatively frequent and may present as diverse clinical-pathological manifestations. Using sensitive detection methods such as HRCT of lungs we may find lung involvement in as many as 70% with systemic sclerosis (SSc). In some CTDs the lung involvement is the leading cause of death and thus it should be actively looked for. Prognosis of different types of lung involvement in CTDs varies and depends on the proportion of inflammatory and fibrotic interstitial changes. Interstitial lung processes with prominent inflammation have usually better prognosis than those with extensive fibrotic changes. Treatment depends on the type of the autoimmune disease and on the phenotype of interstitial lung involvement and is usually based on steroids, immunosuppressive agents and targeted immunological, so-called biological, treatment.

Key words:
connective tissue diseases, lung involvement, prognosis, treatment


Sources

1. Costabel U, duBois RM, Egan JJ. Diffuse parenchymal lung disease. Progress in Respiratory Research, editor Bolliger CT, vol. 36. Basel Switzerland, Karger, 2007.

2. Vašáková M. Intersticiální plicní onemocnění. In Zatloukal P., Fiala P., Votruba J. et al. Pneumologie, Vnitřní lékařství, díl IIIa. Praha 2001. Galén, s.145-169.

3. Vašáková M, Šterclová M, Anton J. Intersticiální plicní procesy – přehled, diferenciální diagnostika, vyšetřovací metody. Praktický lékař 2007; (87) 8: 461-468

4. Antoniou KM, Margaritopoulos G, Economidou F, et al. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 2009; 33(4): 882-96.

5. Bellia M, Cannizzaro F, Scichilone N, et al. HRCT and scleroderma: semiquantitative evaluation of lung damage and functional abnormalities. Radiol Med; 114(2): 190-203.

6. Kartikheyan D. High-resolution computed tomography of the lungs. A pattern approach. London, Hodder Arnold, 2005.

7. Afeltra A, Zennaro D, Garzia P, et al. Prevalence of interstitial lung involvement in patients with connective tissue diseases assessed with high-resolution computed tomography. Scand J Rheumatol 2006; 35(5): 388-94.

8. Ambrosini V, Cancellieri A, Chilosi M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of series. Eur Respir J 2003; 22: 821-826.

9. Boin F, De Fanis U, Bartlett SJ, et al. T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum 2008; 58(4): 1165-74.

10. Vašáková M. Idiopatická plicní fibróza – Novinky v diagnostice a léčbě. Interní Med 2007; 5; 233-236.

11. Cavallasca JA, Caubet M, Helling CA, et al. Cryptogenic organizing pneumonia (COP), as presentation of rheumatoid arthritis. Rheumatol Int 2008; 29(1): 99-101.

12. Parambil JG, Myers JL, Ryu JH. Diffuse alveolar damage: uncommon manifestation of pulmonary involvement in patients with connective tissue diseases. Chest 2006; 130(2): 553-8.

13. Vašáková M, Žáčková P, Matěj R. Syndrom kombinované fibrózy a emfyzému- CPFE syndrom. Praktický lékař 2009; 89(6): 287-289.

14. Swigris JJ, Fischer A, Gillis J, et al. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest 2008;133(1):271-80.

15. Gilson M, Zerkak D, Wipff J, et al. Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. Eur Respir J. 2010;35(1):112-7.

16. Renzoni EA. Interstitial lung disease in systemic sclerosis. Monaldi Arch Chest Dis 2007;67(4):217-28.

17. Metafratzi ZM, Georgiadis AN, Ioannidou CV, et al. Pulmonary involvement in patients with early rheumatoid arthritis. Scand J Rheumatol. 2007;36(5):338-44.

18. Gauhar UA, Gaffo AL, Alarcón GS. Pulmonary manifestations of rheumatoid arthritis. Semin Respir Crit Care Med. 2007;28(4):430-40.

19. Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc. 2007;15;4(5):443-8.

20. Fathi M, Lundberg IE, Tornling G. Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med 2007;28(4):451-8.

21. Ideura G, Hanaoka M, Koizumi T, et al. Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases. Respir Med. 2007;101(7):1406-11.

22. Al-Mutairi S, Al-Awadhi A, Raghupathy R, et al. Lupus patients with pulmonary involvement have a pro-inflammatory cytokines profile. Rheumatol Int. 2007;27(7):621-30.

23. Lazor R. Lung Involvement in Sjogren’s Syndrome: Interstitium, Airways, or Both? Respiration. 2009;78(4):375-376.

24. Fagundes MN, Caleiro MT, Navarro-Rodriguez T, et al. Esophageal involvement and interstitial lung disease in mixed connective tissue disease. Respir Med. 2009;103 (6):854-60.

25. Quismorio FP Jr. Pulmonary involvement in ankylosing spondylitis. Curr Opin Pulm Med 2006; 12(5): 342-5.

Labels
Dermatology & STDs Paediatric rheumatology Rheumatology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account